Effect of Metformin and Megestrol in treatment of Endometrial hyperplasia

Comparative Effect of Using Megestrol Alone and its Combination with Metformin in the Treatment of Endometrial Hyperplasia without Atypia

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20221101056361N1

Enrollment

Registered

2023-04-08

Start date

2022-03-20

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Endometrial hyperplasia. Benign endometrial hyperplasia

Interventions

Intervention 1: Intervention group: 30 people with endometrial hyperplasia will use 40 mg megestrol and placebo from Ectororco for 14 days per month (14 days after the start of period) for 3 months. I

Eligibility

Sex/Gender

Female

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Endometrial Hyperplasia without Hyperplasia No contraindication for the use of Metformin Hb>10 GFR>30 25< BMI 18-75 years old

Exclusion criteria

Exclusion criteria: Use of Metformin in the previous 6 months Liver disease Malabsorption Pregnancy Insulin injection Kidney disease Alcohol consumption

Design outcomes

Primary

Measure	Time frame
Percentage of people with EndometrIal Hyperplasia. Timepoint: The Biginning of study and three monthes later. Method of measurement: with Curettage OF endometer.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParidokht Nourian

Shahre-kord University of Medical Sciences

Paridokht.Nourian @Gmail.com0098383220016

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026